OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $10.81.

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JMP Securities lifted their price objective on shares of OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Stifel Nicolaus lifted their price objective on shares of OptimizeRx from $12.50 to $16.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. Roth Capital reiterated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, B. Riley reiterated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its holdings in OptimizeRx by 9.6% during the 1st quarter. American Century Companies Inc. now owns 15,783 shares of the company's stock worth $137,000 after acquiring an additional 1,387 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in OptimizeRx by 2.1% during the 1st quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company's stock worth $775,000 after acquiring an additional 1,826 shares during the last quarter. Rhumbline Advisers grew its holdings in OptimizeRx by 10.5% during the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company's stock worth $241,000 after acquiring an additional 2,636 shares during the last quarter. Wells Fargo & Company MN grew its holdings in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after acquiring an additional 2,797 shares during the last quarter. Finally, Barclays PLC grew its holdings in OptimizeRx by 13.5% during the 4th quarter. Barclays PLC now owns 30,574 shares of the company's stock worth $148,000 after acquiring an additional 3,640 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Stock Performance

Shares of OPRX opened at $12.65 on Friday. The firm has a 50-day moving average of $11.58 and a 200-day moving average of $8.06. OptimizeRx has a one year low of $3.78 and a one year high of $15.71. The company has a market cap of $234.03 million, a PE ratio of -15.06, a price-to-earnings-growth ratio of 4.40 and a beta of 1.34. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.82 and a quick ratio of 2.82.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. The business had revenue of $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative net margin of 16.33% and a negative return on equity of 0.29%. As a group, equities analysts forecast that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.